Michael Weiser

Michael Weiser was the founder of Foresight Biotherapeutics, Inc. (founded in 2008) serving as Chief Executive Officer & Director.
Dr. Weiser is the founder of Actin Biomed LLC (founded in 2006) serving as Co-Chairman.
Dr. Weiser is the founder of Actin Capital LLC (founded in 2006) serving as Co-Chairman.
Current jobs include Independent Director at Emisphere Technologies, Inc. since 2005, Independent Director at Iovance Biotherapeutics, Inc. since 2018, and Member at American Society of Clinical Oncology, Inc., Alpha Omega Alpha Honor Medical Society, American Society of Hematology, The Association for Research in Vision & Ophthalmology, and The National Medical Honor Society.
Former jobs include Chairman at Ivory Capital Corp., Chairman at Chelsea Therapeutics International Ltd. from 2012 to 2014, Director at VioQuest Pharmaceuticals, Inc. from 2003 to 2009, Director of Research at Paramount BioCapital Asset Management, Inc. from 2001 to 2002, Director at TG Therapeutics, Inc. from 2003 to 2010, Research Director at Paramount BioCapital, Inc. from 1998 to 2006, Director at ZIOPHARM, Inc. from 2003 to 2005, Director at Alacrity Biosciences, Inc., Director at Talon Therapeutics, Inc. from 2002 to 2010, Independent Director at Alaunos Therapeutics, Inc. from 2005 to 2018, Research Director at Paramount BioSciences LLC in 2006, Executive Vice President at Paramount Acquisition Corp.
from 2005 to 2008, and President & Secretary at Seward Sciences, Inc. in 2008.
Education includes undergraduate degree from the University of Vermont in 1987, doctorate from Weill Cornell Medical College, and doctorate from New York University School of Medicine in 1996.